Urge Your Representatives to Retain Funding for Blood Cancer Education Program

My bias is upfront – I like health care reform. I believe all people should have access to health care.
That being said, I did not realize that the FY 2011 budget proposal includes some serious costs to cancer patients. Two CDC cancer programs were eliminated from the president's budget: the Geraldine Ferraro Blood Cancer Education Program and the Gynecologic Cancer Education and Awareness Program, better known as Johanna's Law.
The blood cancer education program, was funded at $4.7 million in FY 2010. Since its inception in 2004, The Geraldine Ferraro Blood Cancer Education Program - named in honor of the former Congresswoman, vice presidential candidate, and multiple myeloma survivor - has funded nearly $35 million in grants to organizations, including The Leukemia & Lymphoma Society (LLS), for programs that benefit blood cancer patients. Programs instituted by LLS with this funding include an educational program for patients living with myeloma, a national forum educating oncology nurses on the management and treatment options for older patients living with blood cancer, and programs to reach underserved patients in both urban and rural settings..

Tell your representatives that cancer patients NEED their support . Urge them to retain funding for the Geraldine Ferraro Blood Cancer Education Program now!

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap